Some have expressed concerns about the risk of myocarditis and unknown longer-term side effects.
Formulary Watch
Latest News
All News
Advertisement
Dexamethasone is recommended by the NIH and the World Health Organization for treating COVID-19.
Specialty drug prices are rising as these therapeutics replace lower-cost therapies.
Novatis is seeking approval for Kymriah in adult patients with advanced follicular lymphoma.
The phase 2/3 trial showed a favorable safety profile, robust immune responses and a vaccine efficacy rate of 90.7% in children 5 to 11 years of age.
Seglentis’ co-crystal formulation targets four complementary pain relief mechanisms.
The label now includes new data from the trial that supported Cyltezo’s application for interchangeability with Humira.
Cigna plans to remove 45 drugs from its Standard Prescription Drug List and add restrictions for other therapeutics.
Cumulative spending on drugs without overall survival data was $1.8 billion in 2018 and surpassed that of drugs with such data.
Xipere is delivered via an injection to the back of the eye to treat macular edema associated with uveitis, a form of eye inflammation.
Advertisement
Specialty medicines are now 53% of spending, up from 27% in 2010 and driven by growth in autoimmune and oncology therapies.
Genentech’s Susvimo is a refillable implant that delivers medication continuously for up to six months.
Oncopeptides will close down its business units in the United States and Europe to focus exclusively on being a Sweden-based R&D company.
Developed by Regeneron Pharmaceuticals and Sanofi, Dupixent reduced severe asthma attacks and improved lung function in children 6 to 11 years.
A phase 3 trial of Pfizer and BioNTech’s COVID-19 vaccine booster demonstrates an efficacy rate of 95.6%.
If a patient does not remain on the drug for at least three months due to effectiveness or tolerability, a significant portion of the drug cost will be refunded to Point32Health.
Tecentriq is the first cancer immunotherapy available for adjuvant treatment of non-small cell lung cancer (NSCLC).
Treating and managing patients with paroxysmal nocturnal hemoglobinuria is expensive and requires constant surveillance by the provider and health plan.
Dr. Reddy’s received FDA approval for two strengths of lenalidomide for the treatment of patients with multiple myeloma.
AmerisourceBergen/Xcenda survey finds payers believe biosimilars provide costs savings, and they are expected to continuing contracting with manufacturers.
Glass was found in one vial of Cubicin, which treats patients with Staph infections of the skin and blood.
Express Scripts will put the first interchangeable biosimilar insulin on its National Preferred Formulary and exclude Lantus, the reference product.
COVID-19 travel restrictions have hindered the FDA’s ability to inspect European manufacturing facilities for bimekizumab, which is under review for the treatment of patients with psoriasis.
ZIMHI is the second product approved by the FDA to counteract opioid, and it is a high-dose naloxone expected to be launched in the first quarter of 2022.
Most of the solutions have established systems to track patient outcomes over time, and several include performance guarantees as part of their solution.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Myqorzo is now available for rare heart condition at a $108,400 annual price
2
FAQ: The uncertain future of enhanced ACA premium subsidies and what it means for U.S. healthcare
3
Medicaid tech companies pledge $600 million to help states update systems
4
Study of antibody-Keytruda combination seeds hope for overcoming immune checkpoint inhibitor resistance, use of biomarkers
5